Lercadip (Lercanidipine Hydrochloride)

Lercadip belongs to the calcium channel blocker class and is used to manage elevated blood pressure.

• Hypertension: lowers elevated blood pressure, helping to reduce the risk of cardiovascular events.

• Lercanidipine hydrochloride selectively inhibits L-type calcium channels in vascular smooth muscle, which reduces calcium influx, leading to relaxation of arterial walls, vasodilation, and a consequent decrease in peripheral vascular resistance and blood pressure.

Lercadip may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Flushing: sensation of warmth and redness, especially of the face.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness: light‑headed feeling, particularly when standing quickly.
• Fatigue: general tiredness without exertion.
• Tachycardia: increased heart rate.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure that may cause fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Allergic reactions: rash, itching, or swelling of the face and throat.
• Angioedema: rapid swelling of deeper skin layers.
• Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy with Lercadip, several safety considerations should be observed.

• Blood pressure monitoring: regularly assess to ensure therapeutic targets are met.
• Liver function: evaluate hepatic status, especially in patients with known liver disease.
• Elderly patients: start at the lowest effective dose and monitor for orthostatic effects.
• Concomitant antihypertensives: adjust doses to avoid excessive hypotension.
• CYP3A4 inhibitors: avoid strong inhibitors that may raise drug levels.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercadip can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Other antihypertensives (e.g., ACE inhibitors, ARBs): risk of additive blood‑pressure lowering.
• Grapefruit juice: can elevate drug levels and precipitate hypotension.

Moderate Interactions (Monitor Closely)

• Other dihydropyridine calcium channel blockers: may produce additive vasodilatory effects.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response.
• Beta‑blockers: may require dose adjustments to maintain hemodynamic stability.